We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+8.2%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$667M
AUM Growth
+$23.1M
Cap. Flow
+$3.29M
Cap. Flow %
0.49%
Top 10 Hldgs %
55.8%
Holding
54
New
10
Increased
20
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$24.5M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$21.8M
3
TWST icon
Twist Bioscience
TWST
+$14M
4
JANX icon
Janux Therapeutics
JANX
+$7.44M
5
AQST icon
Aquestive Therapeutics
AQST
+$6.99M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$13.4M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$12.6M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$11M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$10.9M
5
AXSM icon
Axsome Therapeutics
AXSM
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AQST icon
26
Aquestive Therapeutics
AQST
$630M
$8.95M 1.34%
+1,796,750
New +$6.99M
JANX icon
27
Janux Therapeutics
JANX
$1.1B
$7.77M 1.17%
+171,105
New +$7.44M
VKTX icon
28
Viking Therapeutics
VKTX
$3.75B
$7.66M 1.15%
120,982
+2,022
+2% +$119K
XENE icon
29
Xenon Pharmaceuticals
XENE
$5.81B
$6.53M 0.98%
+165,800
New +$6.69M
STOK icon
30
Stoke Therapeutics
STOK
$2.04B
$5.89M 0.88%
+479,452
New +$6.79M
RPTX
31
DELISTED
Repare Therapeutics
RPTX
$5.64M 0.85%
1,639,849
– –
NTLA icon
32
Intellia Therapeutics
NTLA
$1.8B
$5.5M 0.82%
267,557
-175,946
-40% -$4.06M
ZNTL icon
33
Zentalis Pharmaceuticals
ZNTL
$360M
$5.39M 0.81%
1,465,801
+15,801
+1% +$57.4K
TRVI icon
34
Trevi Therapeutics
TRVI
$2.39B
$5.14M 0.77%
1,538,517
+28,343
+2% +$84.3K
WVE icon
35
Wave Life Sciences
WVE
$993M
$5.12M 0.77%
+624,471
New +$3.73M
ARCT icon
36
Arcturus Therapeutics
ARCT
$432M
$5.09M 0.76%
+219,508
New +$4.7M
HOWL icon
37
Werewolf Therapeutics
HOWL
$45.8M
$5.06M 0.76%
2,388,011
– –
ADAP
38
DELISTED
Adaptimmune Therapeutics
ADAP
$4.84M 0.73%
5,095,912
– –
ALXO icon
39
ALX Oncology
ALXO
$277M
$4.39M 0.66%
2,409,862
+228,998
+11% +$851K
PTCT icon
40
PTC Therapeutics
PTCT
$5.85B
$3.33M 0.5%
+89,715
New +$3M
ETNB
41
DELISTED
89bio
ETNB
$2.44M 0.37%
330,000
-791,736
-71% -$6.66M
RGNX icon
42
Regenxbio
RGNX
$638M
$525K 0.08%
50,000
-507,076
-91% -$6.18M
SLDB icon
43
Solid Biosciences
SLDB
$1.05B
$80.3K 0.01%
+11,518
New +$93.4K
ALKS icon
44
Alkermes
ALKS
$7.95B
– –
-557,556
Closed -$13.4M
ALLK
45
DELISTED
Allakos
ALLK
– –
-344,900
Closed -$345K
AVDL
46
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-783,242
Closed -$11M
AXSM icon
47
Axsome Therapeutics
AXSM
$10.4B
– –
-132,312
Closed -$10.7M
FULC icon
48
Fulcrum Therapeutics
FULC
$294M
– –
-1,444,851
Closed -$8.96M
HLVX
49
DELISTED
HilleVax
HLVX
– –
-645,085
Closed -$9.33M
IMTX icon
50
Immatics
IMTX
$1.44B
– –
-417,810
Closed -$4.85M
1
2
3

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q3 2024 Portfolio in Review

As of Q3 2024, MPM BioImpact held 54 positions worth $667M, up 3.6% from $644M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

MPM BioImpact's Q3 2024 filing shows 10 new, 20 increased, 7 reduced and 11 closed positions. Its largest new stake was Rocket Pharmaceuticals: 1,066,373 shares worth $19.7M. The largest sale was Alkermes, an estimated $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM BioImpact's largest Q3 2024 buy was Rocket Pharmaceuticals: 1,066,373 shares worth $19.7M.
  • MPM BioImpact added most to Avidity Biosciences in Q3 2024, an estimated $24.5M increase.
  • MPM BioImpact's biggest Q3 2024 reduction was 89bio, cutting an estimated $6.66M.
  • MPM BioImpact fully exited Alkermes in Q3 2024, selling an estimated $13.4M.
  • MPM BioImpact's ten largest holdings make up 56% of its $667M portfolio in Q3 2024.
  • MPM BioImpact opened 10 new positions and closed 11 in Q3 2024.
  • MPM BioImpact's portfolio value rose 3.6% quarter-over-quarter to $667M.

Based on MPM BioImpact's 13F filing for Q3 2024, filed 13 Nov 2024.